The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma

Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate

(2009) Zhao Chen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS

Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

(2009) Katherine K. Matthay et al.   JOURNAL OF CLINICAL ONCOLOGY

18F-FDG PET/CT as an Indicator of Progression-Free and Overall Survival in Osteosarcoma

(2009) C. M. Costelloe et al.   JOURNAL OF NUCLEAR MEDICINE

Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells

(2009) J. Yun et al.   SCIENCE

Lack of correlation between MYCN expression and the Warburg effect in neuroblastoma cell lines

(2008) Danielle J Smith et al.   BMC CANCER

Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-d-glucose under hypoxia in lung cancer cell lines

(2008) Medhi Wangpaichitr et al.   MOLECULAR CANCER THERAPEUTICS

3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs

(2008) Linda Strandberg Ihrlund et al.   Molecular Oncology

Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: A report from the Children's Oncology Group

(2008) Peter E. Zage et al.   PEDIATRIC BLOOD & CANCER